MARKET

AGEN

AGEN

Agenus
NASDAQ
6.15
-0.57
-8.48%
After Hours: 6.20 +0.05 +0.81% 19:46 07/18 EDT
OPEN
6.70
PREV CLOSE
6.72
HIGH
6.71
LOW
6.12
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
18.74
52 WEEK LOW
1.380
MARKET CAP
168.61M
P/E (TTM)
-0.7114
1D
5D
1M
3M
1Y
5Y
1D
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
NASDAQ · 2d ago
Weekly Report: what happened at AGEN last week (0707-0711)?
Weekly Report · 6d ago
Agenus unit, MiNK surges after peer-reviewed data for lead drug
Seeking Alpha · 07/11 15:12
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
NASDAQ · 07/10 13:11
Zacks.com featured highlights Yext, Agenus and NCR Voyix
NASDAQ · 07/10 08:42
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
NASDAQ · 07/09 16:26
3 Top Earnings Acceleration Stocks to Buy for 2H25
Barchart · 07/08 15:14
Agenus’s Strategic Advancements and Promising Clinical Data Boost Investor Confidence
TipRanks · 07/08 10:25
More
About AGEN
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.